Literature DB >> 19440215

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.

D Olcaydu, R C Skoda, R Looser, S Li, M Cazzola, D Pietra, F Passamonti, E Lippert, S Carillo, F Girodon, A Vannucchi, N S Reading, J T Prchal, C Ay, I Pabinger, H Gisslinger, R Kralovics.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19440215     DOI： 10.1038/leu.2009.110

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  24 in total

1.  Molecular basis and clonal evolution of myeloproliferative neoplasms.

Authors:  Roland Jäger; Robert Kralovics
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

2.  No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

Review 3.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

4.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

5.  Myelofibrosis 2012: it's complicated.

Authors:  Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal:  Ther Adv Hematol       Date:  2012-06

Review 6.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

7.  The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Elisa Rumi; Ashot Harutyunyan; Francesco Passamonti; Daniela Pietra; Cristiana Pascutto; Tiina Berg; Roland Jäger; Emma Hammond; Mario Cazzola; Robert Kralovics
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

8.  Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Authors:  Elisa Rumi; Francesco Passamonti; Chiara Elena; Daniela Pietra; Luca Arcaini; Cesare Astori; Silvia Zibellini; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

9.  Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.

Authors:  Eun-Hyung Yoo; Kyung-Jin Park; Hong-Hee Won; Jun-Hee Park; Jong-Ho Park; Seung-Tae Lee; Hee-Jin Kim; Soo-Mee Bang; Hyun-Sook Chi; Chul Won Jung; Sun-Hee Kim; Hongseok Yun; Choong-Hyun Sun; Inho Park; Seungmook Lee; Clarence Lee; Barry Merriman; Raymond Luo; Eileen Hwee Hong Tan; Keun-Joon Park; Na-Kyung Yoo; Jason J Kang; Jong-Won Kim
Journal:  J Clin Lab Anal       Date:  2016-05-02       Impact factor: 2.352

10.  Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations.

Authors:  Stephen E Langabeer; Karl Haslam; Jennifer Linders; Melanie J Percy; Eibhlin Conneally; Amjad Hayat; Brian Hennessy; Maeve Leahy; Karen Murphy; Margaret Murray; Fionnuala Ni Ainle; Patrick Thornton; Jeremy Sargent
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.